ClinicalTrials.gg
RecruitingNCT07835399PBMT in MCIUpdated Sep 22, 2026

Efficacy and Safety of Photobiomodulation Therapy in Patients With Mild Cognitive Impairment and Mild Alzheimer's Disease

An interventional study of Photobiomodulation and Photobiomodulation in Mild Cognitive Impairment (MCI), Mild Alzheimer Disease and Dementia, sponsored by Jun Xu. Recruiting at 1 site in China. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Jun Xu · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Jun 2024, registered Jun 2026).
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 309 studies in Cognitive Dysfunction with a site in China — 143 open to participants now, 155 under way, 8 of them phase 3. Cognitive Dysfunction · China.

Planned enrollment
184th of 190
20 · median 110
Started
2024
with 44 others
No phase
138 of 309
60 open now
Primary completion
2026-12
later than 72 of 154 live
Registered
282nd of 309
by date

Among the 309 studies in Cognitive Dysfunction with a site in China, this one is the 184th largest by planned enrollment of the 190 interventional ones that give a count, is one of 45 that started in 2024, is one of 138 with no phase, reaches primary completion later than 72 of the 154 other live ones, and was the 282nd registered.

Cognitive Dysfunction

3,876 studies on the registry are indexed under Cognitive Dysfunction; 1,119 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

143 of the 309 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:

138 more — sign in →

All 143 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 753 Cognitive Dysfunction studies recruiting now, 364 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 309 studies in Cognitive Dysfunction with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if photobiomodulation therapy (PBMT) can help treat mild cognitive impairment and mild Alzheimer's disease in adults aged 50 to 85 years. It will also learn about the safety of PBMT. The main questions it aims to answer are:

Does PBMT improve cognitive function in adults with mild cognitive impairment or mild Alzheimer's disease? What medical problems do participants have when using PBMT? Researchers will compare an active PBMT device to a sham (look-alike) device that delivers no active light therapy to see if PBMT improves cognitive function.

Participants will:

Use a transcranial near-infrared light therapy device (or a matching sham device) once a day for 20 minutes, 5 days a week, for 6 months Visit the clinic for cognitive, mood, sleep, and daily-function assessments at the start of the study, at Month 3, and at Month 6 Have brain MRI scans at the start of the study, at Month 3, and at Month 6

Read the detailed description

Alzheimer's disease and its prodromal stage, mild cognitive impairment, are characterized by progressive neurodegeneration for which disease-modifying options remain limited. Photobiomodulation therapy (PBMT) delivers non-ionizing red and near-infrared light to neural tissue, where it is absorbed by cytochrome c oxidase in the mitochondrial respiratory chain. This is hypothesized to enhance ATP production, modulate reactive oxygen species and intracellular signaling, increase regional cerebral blood flow, and support neuroprotective and anti-inflammatory processes, providing the biological basis for evaluating PBMT as a non-invasive intervention in early Alzheimer's disease.

This is a single-center, prospective, randomized, double-blind, sham-controlled trial conducted at the Department of Cognitive Disorders, Beijing Tiantan Hospital, Capital Medical University. Eligible participants are randomly allocated in a 1:1 ratio to the active PBMT arm or the sham-control arm using a computer-generated randomization sequence. To preserve double blinding, the active and sham devices are identical in appearance and operation; the sham device emits visible light at a wavelength without established photobiomodulatory effect, so that neither participants nor outcome assessors can distinguish between arms. Treatment is self-administered at home according to a fixed schedule over the 6-month intervention period, with adherence monitored through device usage records and scheduled study visits.

Assessments are performed at baseline, Month 3, and Month 6 by trained raters blinded to group allocation. Beyond the clinical and neuropsychological battery, structural and functional MRI is used to examine treatment-associated changes in cortical and hippocampal volume, white matter integrity, and cerebral blood flow perfusion, supporting exploratory analysis of the candidate mechanisms above. Safety is monitored throughout via adverse-event reporting, device-related event tracking, and review of skin and nasal tolerability. Efficacy analyses compare between- and within-group change from baseline across the cognitive, neuropsychiatric, sleep, daily-function, and caregiver-burden domains, with imaging and tolerability data used to characterize the safety profile and explore possible mechanisms of action of PBMT in AD-derived MCI and mild AD.

03

Conditions studied

  • Mild Cognitive Impairment (MCI)
  • Mild Alzheimer Disease
  • Dementia

Keywords

  • Photobiomodulation
  • Transcranial photobiomodulation
  • Near-infrared light therapy
  • Alzheimer's disease
  • Mild cognitive impairment
  • Dementia;
  • Neuromodulation
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

1、Inclusion Criteria:

  1. Age 50-85 years
  2. Meet the 2011 NIA-AA diagnostic criteria for "MCI due to AD" or "probable AD dementia," or meet the 2018 NIA-AA "ATN" diagnostic framework for AD;
  3. 0.5 ≤ CDR ≤ 2; for illiterate: ≤ 13; for primary school education: MMSE ≤ 19; for junior high school or above: MMSE ≤ 24; for MCI: ADL-20 ≤ 22; for mild AD: ADL-20 > 22;
  4. Able to understand instructions and cooperate with serological tests, scale assessments, and brain MRI;
  5. Have a study partner who can participate throughout the study。

2、Exclusion Criteria:

  1. Inability to complete serological tests, scale assessments, or brain MRI due to severe visual/auditory impairment, severe neuropsychiatric symptoms, to MRI, etc.
  2. History of other central nervous system injuries causing cognitive decline (e.g., severe traumatic brain injury, severe CNS infection, carbon monoxide poisoning, alcohol abuse, primary CNS tumors)
  3. Unstable or severe heart, lung, liver, kidney, or hematopoietic diseases, poor general health
  4. Short due to major diseases (e.g., end-stage cancer cachexia)
  5. Large skin lesions or scars on the scalp, or poor heat dissipation that cannot tolerate PBMT
  6. Patients with photosensitivity disorders
  7. Abnormal nasal structure (deviated septum or large polyps); bacterial or viral infection; nasal dryness/bleeding; nasopharyngeal carcinoma unsuitable for intranasal device insertion.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Active PBMT

    Use the transcranial photobiomodulation device at 810 nm once daily for 20 minutes per session, for 5 consecutive days, followed by 2 days off.

    Device: Photobiomodulation

  • Sham comparator
    Sham PBMT

    Use the transcranial photobiomodulation device at 660 nm once daily for 20 minutes per session, for 5 consecutive days, followed by 2 days off.

    Device: Photobiomodulation

Interventions

  • DevicePhotobiomodulation

    transcranial photobiomodulation

  • DevicePhotobiomodulation

    transcranial photobiomodulation

06

What researchers measure

Primary outcomes

  1. Mini-Mental State Examination

    The Mini-Mental State Examination (MMSE) assesses orientation, registration, attention and calculation, recall, and language using 11 items. Total scores range from 0 to 30; lower scores indicate worse cognitive function and higher scores indicate better cognitive function.

    Time frame: Baseline, Month 3, Month 6

  2. Montreal Cognitive Assessment

    The Montreal Cognitive Assessment (MoCA) assesses visuospatial and executive function, naming, attention, language, abstraction, delayed recall, and orientation. Total scores range from 0 to 30; higher scores indicate better cognitive function and lower scores indicate worse cognitive function.

    Time frame: Baseline, Month 3, Month 6

  3. Alzheimer's Disease Assessment Scale-Cognitive Subscale

    The Alzheimer's Disease Assessment Scale-Cognitive Subscale, 11-item version (ADAS-Cog-11), assesses cognitive domains including memory, language, orientation, and praxis. The total score ranges from 0 to 70, with 0 indicating the least cognitive impairment and 70 indicating the most severe cognitive impairment. Higher scores indicate worse cognitive function. A decrease in score indicates improvement, whereas an increase indicates worsening.

    Time frame: Baseline, Month 3, Month 6

  4. Clinical Dementia Rating

    The Clinical Dementia Rating (CDR) assesses cognition and daily functioning. The CDR Sum of Boxes (CDR-SB) ranges from 0 to 18; higher scores indicate greater impairment. The global CDR score ranges from 0 to 3: 0 = normal, 0.5 = questionable, 1 = mild, 2 = moderate, and 3 = severe; higher scores indicate worse outcomes.

    Time frame: Baseline, Month 3, Month 6

  5. Magnetic Resonance Imaging

    Magnetic resonance imaging (MRI) compares differences in cortical/hippocampal atrophy, white matter degeneration, and cerebral blood flow perfusion before and after treatment.

    Time frame: Baseline, Month 3, Month 6

Secondary outcomes

  1. Hamilton Depression Rating Scale

    The 17-item Hamilton Depression Rating Scale (HAMD-17) is a clinician-rated assessment of depression severity covering mood, anxiety, somatic symptoms, cognition, sleep, and related symptoms. Total scores range from 0 to 52; higher scores indicate more severe depression and a worse outcome.

    Time frame: Baseline, Month 3, Month 6

  2. Hamilton Anxiety Rating Scale

    The Hamilton Anxiety Rating Scale (HAMA) is a 14-item, clinician-rated assessment of psychic and somatic anxiety. Total scores range from 0 to 56; higher scores indicate greater anxiety severity and a worse outcome.

    Time frame: Baseline, Month 3, Month 6

  3. Neuropsychiatric Inventory

    The Neuropsychiatric Inventory (NPI) assesses behavioral and psychological symptoms of dementia across 12 domains. It measures symptom frequency, severity, and caregiver distress. The total score ranges from 0 to 144, with higher scores indicating more severe neuropsychiatric symptoms.

    Time frame: Baseline, Month 3, Month 6

  4. Pittsburgh Sleep Quality Index

    The Pittsburgh Sleep Quality Index (PSQI) is a 19-item, self-rated assessment of sleep quality over the previous month across seven components. Total scores range from 0 to 21; higher scores indicate poorer sleep quality and a worse outcome.

    Time frame: Baseline, Month 3, Month 6

  5. Activities of Daily Living Scale

    The 20-item Activities of Daily Living Scale (ADL-20) assesses basic and instrumental activities of daily living. Total scores range from 20 to 80; higher scores indicate greater dependence and worse functional ability, while lower scores indicate greater independence.

    Time frame: Baseline, Month 3, Month 6

  6. Caregiver Burden Inventory

    The Caregiver Burden Inventory (CBI) assesses time-dependence, developmental, physical, social, and emotional burden. Total scores range from 0 to 96; higher scores indicate greater caregiver burden and a worse outcome.

    Time frame: Baseline, Month 3, Month 6

07

Study locations

1 of 1 sites recruiting
  • Department of Cognitive Disorders, Beijing Tiantan Hospital, Capital Medical University
    Beijing, China
    Recruiting
    • Qiwei Ren · Contactrenqiwei0828@163.com · 86-16619725364
    • JUN XU, Chief Physician, Professor · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlines results in a publication

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Starting 6 months after publication, all IPD and supporting information will be made available.

Access criteria: All information regarding participants' data on primary and secondary outcome measurements will be used in publication.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.

Of 1,449 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 30 months is above that.

Counting every sponsor, half of 1,518 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Sep 22, 2026
StartActual
Jun 15, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07835399
Lead sponsor
Jun Xu
Collaborators
Shanghai Jinze Biotechnology Co. Ltd.
Responsible party
Jun Xu (Chief Physician, Professor, Department of Cognitive Disorders, Beijing Tiantan Hospital) — Sponsor-investigator
First posted
Sep 22, 2026
Start date
Jun 15, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 22, 2026

Study contacts

Qiwei Ren
Contact
renqiwei0828@163.com
86-16619725364

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion